Inland Peptides
Inland Peptides

Pemvidutide

Research Snapshot Last reviewed October 2026
No

Approved by the FDA for human use

Yes

Studied in human clinical trials

Yes

Published human research

Yes

Published animal research

Primary research areas
  • Fatty liver disease and weight loss

Overview

Pemvidutide is an experimental peptide developed by Altimmune for fatty liver disease and weight loss. It acts on GLP-1 and glucagon receptors.

Pemvidutide is not approved by the Food and Drug Administration for human use, and no prescription version exists. It should only be used within an approved clinical study and never taken without a doctor’s authorization.

What is it being studied for?

Researchers study pemvidutide for obesity and fatty liver disease, including metabolic dysfunction-associated steatohepatitis, or MASH, which involves liver inflammation and damage.

GLP-1 signaling affects appetite and blood sugar. Glucagon signaling affects energy use and liver metabolism.

What has research found?

In a placebo-controlled human study, pemvidutide reduced liver fat and body weight over 12 weeks.

Reported side effects were mainly digestive.

Published mouse research also found reduced body weight, liver fat, and markers of liver inflammation.

FDA status and development history

Pemvidutide, also known as ALT-801, is being developed by Altimmune. It is not FDA-approved for human use.